title: A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012.
abstract: BACKGROUND
  Panitumumab is a fully human monoclonal antibody, directed against the epidermal growth factor receptor, that was shown to be effective in third-line metastatic colorectal cancer. We performed a retrospective analysis of patients with chemo-refractory non-KRAS-mutated metastatic colorectal cancer, who received panitumumab at the Jewish General Hospital in Montreal, Canada, between 2009 and 2012.
  
  
  METHODS
  This chart review included 44 patients (median age: 60 years; performance status: 0-3), of whom 50% had already received three lines of treatment. The primary endpoint was progression-free survival (pfs). Secondary endpoints were overall survival and safety. Tumour progression was determined by radiologic assessments performed once every 3 months per clinical guidelines or by clinical deterioration as determined by the clinician-investigator.
  
  
  RESULTS
  In our sample, median pfs was 21.86 ± 5.23 weeks (95% confidence interval: 12.9 to 36.9 weeks) and overall survival was 35.14 ± 7.75 weeks (95% confidence interval: 25.6 to 73.4 weeks) with a median of 5 cycles of panitumumab treatment. The most frequently reported toxicities with panitumumab were skin toxicity (16.2% grade 3) and hypomagnesemia (10.8% grade 3). No infusion reactions were reported.
  
  
  CONCLUSIONS
  Despite a small sample size from a single institution, our survival and efficacy data are encouraging and comparable to results obtained from the registration panitumumab trial. Our findings suggest that panitumumab can be effective and tolerable in a real-world setting.
authors.affiliation: Department of Oncology, McGill University, and the Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC.
authors.forename: A
authors.initials: A
authors.lastname: Mamo
authors.forename: M Cardoso
authors.initials: MC
authors.lastname: Nogueira
authors.forename: G
authors.initials: G
authors.lastname: Batist
authors.forename: M
authors.initials: M
authors.lastname: Palumbo
authors.forename: L
authors.initials: L
authors.lastname: Panasci
authors.forename: C
authors.initials: C
authors.lastname: Ferrario
authors.forename: P
authors.initials: P
authors.lastname: Chaudhury
authors.forename: P
authors.initials: P
authors.lastname: Metrakos
authors.forename: P
authors.initials: P
authors.lastname: Kavan
keywords: Metastatic colorectal cancer; overall survival; panitumumab; progression-free survival; safety
references.citation: J Clin Oncol. 2010 Nov 1;28(31):4706-13
references.pmid: 20921462
references.citation: J Clin Oncol. 2009 Mar 1;27(7):1130-6
references.pmid: 19124802
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1201-8
references.pmid: 14993230
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1626-34
references.pmid: 18316791
references.citation: Cancer Res. 1999 Mar 15;59(6):1236-43
references.pmid: 10096554
references.citation: J Clin Oncol. 2007 May 1;25(13):1658-64
references.pmid: 17470858
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5335-43
references.pmid: 18854570
references.citation: N Engl J Med. 2009 Apr 2;360(14):1408-17
references.pmid: 19339720
references.citation: Clin Colorectal Cancer. 2008 May;7(3):184-90
references.pmid: 18621636
references.citation: Ann Oncol. 2008 Mar;19(3):508-15
references.pmid: 17998284
references.citation: J Clin Oncol. 2009 Feb 10;27(5):663-71
references.pmid: 19114683
references.citation: Nat Rev Cancer. 2005 May;5(5):341-54
references.pmid: 15864276
references.citation: N Engl J Med. 2008 Oct 23;359(17):1757-65
references.pmid: 18946061
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3003-15
references.pmid: 15210739
references.citation: J Clin Oncol. 2008 May 10;26(14):2311-9
references.pmid: 18390971
references.citation: Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90
references.pmid: 14967460
references.citation: N Engl J Med. 2007 Nov 15;357(20):2040-8
references.pmid: 18003960
references.citation: Semin Oncol. 2006 Aug;33(4):369-85
references.pmid: 16890793
references.citation: Cancer Res. 2007 Mar 15;67(6):2643-8
references.pmid: 17363584
references.citation: Br J Cancer. 2007 Apr 23;96(8):1166-9
references.pmid: 17375050
references.citation: J Clin Oncol. 2008 Jan 20;26(3):374-9
references.pmid: 18202412
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313